Status:
COMPLETED
Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor
Lead Sponsor:
Pfizer
Conditions:
Metastatic Breast Cancer
Eligibility:
All Genders
18+ years
Brief Summary
A retrospective study of de-identified (to preserve patient privacy) patient information from the Flatiron Health Analytic Database to compare effectiveness (i.e., overall survival) of first line palb...
Eligibility Criteria
Inclusion
- Confirmed HR+/HER2- status after MBC diagnosis.
- Received palbociclib + AI or AI as first-line therapy
Exclusion
- Evidence of prior treatment with other CDK4/6I, AI, tamoxifen, raloxifene, toremifene, or Fulvestrant for MBC
- First structured activity greater than 90 days after MBC diagnostic date
- Treatment with a CDK4/6 inhibitor as part of a clinical trial
Key Trial Info
Start Date :
September 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2021
Estimated Enrollment :
2888 Patients enrolled
Trial Details
Trial ID
NCT05361655
Start Date
September 1 2021
End Date
September 1 2021
Last Update
June 7 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
10017
New York, New York, United States, 10017